Semaglutide
For educational and research reference only. Not medical advice. Not for human or animal use. Research peptides are Research Use Only (RUO).
Amino Acid Sequence
31 amino acid modified GLP-1 analogAn interactive map of key discoveries, clinical trials, and major findings across 8 research milestones.
Semaglutide was developed by Novo Nordisk as a long-acting GLP-1 receptor agonist, engineered with a fatty acid chain for albumin binding to extend half-life to ~1 week.
Timeline compiled from published research literature for educational reference. Dates reflect first major publication or event; subsequent research continues to refine findings.
Semaglutide is a lab-modified version of a hormone your gut naturally releases after eating, called GLP-1. Normally, GLP-1 breaks down in minutes. Scientists modified it so it lasts about a week in your body. Think of it like upgrading a candle that burns for 5 minutes into one that burns for 7 days — same type of light, just engineered to last much longer. It tells your brain you are full and helps regulate blood sugar.
Semaglutide activates the GLP-1 receptor, mimicking the incretin effect: stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. Its albumin-binding fatty acid chain extends its half-life to approximately 7 days.
Extensive human clinical trial data across multiple Phase III programs (SUSTAIN, PIONEER, STEP trials). FDA-approved as Ozempic® (injectable, diabetes), Rybelsus® (oral, diabetes), and Wegovy® (injectable, obesity). Thousands of patients studied across dozens of clinical trials.
Preclinical animal pharmacology established the mechanism and safety profile before human trials.
Comprehensive receptor binding studies, pharmacokinetic modeling, and structure-activity relationship research.
Both contain semaglutide. Ozempic is approved for type 2 diabetes (doses up to 2mg/week). Wegovy is approved for chronic weight management (dose of 2.4mg/week). Same molecule, different approved indications and dosing.
Yes. Semaglutide is a modified peptide — a 31-amino-acid analog of human GLP-1 with specific amino acid substitutions and a fatty acid chain that extends its half-life from minutes to approximately one week.
Highly stable due to engineered modifications (fatty acid chain, amino acid substitutions). Commercial products stable at room temperature for defined periods. Oral formulation uses SNAC absorption enhancer.
Research Use Only
For educational and research reference only. Not medical advice. Not for human or animal use. Research peptides are Research Use Only (RUO).